NeologicsBio

Neologics Bio is a preclinical-stage biotechnology company pioneering the development of programmable cytokines to treat cancer and autoimmune disorders. Founded by Dr. K. Christopher Garcia of Stanford University, the company leverages deep expertise in structural biology and protein engineering to design cytokines with optimized receptor signaling profiles. Their platform aims to overcome the narrow therapeutic index of wild-type cytokines by decoupling potent anti-tumor activity from severe systemic toxicities. Neologics Bio is currently advancing a pipeline of engineered interleukin variants, including IL-2 and IL-12, toward clinical development.